J Clin Aesthet Dermatol. 2021;14(8):14–21. by James Q. Del Rosso, DO; Guy Webster, MD; Jonathan S. Weiss, MD; Neal D. Bhatia, MD; Linda Stein Gold, MD; and Leon Kircik, MD Dr. Del Rosso is with JDR Dermatology Research and Thomas Dermatology in Las Vegas, Nevada, and Clinical Research at Advanced Dermatology and Cosmetic Surgery in
Objective. We sought to evaluate the safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study.